Penumbra, Inc. (NYSE:PEN) EVP Sells $107,520.00 in Stock

Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts sold 600 shares of Penumbra stock in a transaction on Monday, July 1st. The shares were sold at an average price of $179.20, for a total value of $107,520.00. Following the transaction, the executive vice president now owns 62,288 shares of the company’s stock, valued at approximately $11,162,009.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Johanna Roberts also recently made the following trade(s):

• On Monday, June 3rd, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $188.90, for a total value of $113,340.00.
• On Monday, May 13th, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $207.41, for a total value of $124,446.00.

Penumbra Stock Performance

Shares of PEN traded up $1.45 during trading hours on Wednesday, hitting $177.44. The stock had a trading volume of 130,530 shares, compared to its average volume of 344,588. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.12 and a quick ratio of 3.51. Penumbra, Inc. has a 12 month low of $170.59 and a 12 month high of $341.23. The firm has a market capitalization of $6.88 billion, a PE ratio of 74.87, a PEG ratio of 1.82 and a beta of 0.55. The stock has a fifty day moving average price of $192.82 and a 200 day moving average price of $224.55.

Penumbra (NYSE:PEN) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.41 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.01). Penumbra had a return on equity of 7.83% and a net margin of 8.52%. The firm had revenue of $278.70 million during the quarter, compared to the consensus estimate of $274.94 million. During the same period in the previous year, the firm earned $0.23 EPS. The business’s revenue was up 15.5% on a year-over-year basis. Analysts anticipate that Penumbra, Inc. will post 2.87 EPS for the current year.

Institutional Trading of Penumbra

Hedge funds have recently bought and sold shares of the stock. Benjamin F. Edwards & Company Inc. grew its holdings in Penumbra by 171.8% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 106 shares of the company’s stock valued at $27,000 after purchasing an additional 67 shares during the period. Mather Group LLC. bought a new stake in Penumbra during the first quarter valued at about $29,000. Signaturefd LLC grew its holdings in Penumbra by 27.2% during the fourth quarter. Signaturefd LLC now owns 215 shares of the company’s stock valued at $54,000 after purchasing an additional 46 shares during the period. Quest Partners LLC bought a new stake in Penumbra during the fourth quarter valued at about $71,000. Finally, Picton Mahoney Asset Management purchased a new position in shares of Penumbra in the fourth quarter valued at about $88,000. Institutional investors own 88.88% of the company’s stock.

Wall Street Analysts Forecast Growth

PEN has been the subject of a number of recent research reports. Needham & Company LLC reiterated a “hold” rating on shares of Penumbra in a research note on Wednesday, May 8th. Canaccord Genuity Group decreased their price target on Penumbra from $284.00 to $272.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Piper Sandler decreased their price target on Penumbra from $290.00 to $260.00 and set an “overweight” rating for the company in a research note on Wednesday, May 8th. Finally, Truist Financial decreased their price target on Penumbra from $290.00 to $280.00 and set a “buy” rating for the company in a research note on Friday, March 22nd. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $293.10.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.